The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| CYTOKINETICS INC | COM | 23282W605 | 47,105,547 | 714,695 | SH | SOLE | 714,695 | 0 | 0 | ||
| Eikon Therapeutics, Inc. | COM | 282564103 | 15,627,203 | 1,943,682 | SH | SOLE | 1,943,682 | 0 | 0 | ||
| Pharvaris N.V. | COM | N69605108 | 151,576,589 | 4,778,581 | SH | SOLE | 4,778,581 | 0 | 0 | ||
| Relay Therapeutics, Inc. | COM | 75943R102 | 22,562,500 | 1,250,000 | SH | SOLE | 1,250,000 | 0 | 0 | ||
| VERACYTE, INC. | COM | 92337F107 | 9,208,000 | 200,000 | SH | SOLE | 200,000 | 0 | 0 | ||
| Xenon Pharmaceuticals Inc. | COM | 98420N105 | 5,950,400 | 160,000 | SH | SOLE | 160,000 | 0 | 0 | ||